These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29726595)

  • 1. Development and validation of an HPLC-UV method for quantification of elvitegravir and two other new antiretrovirals, dolutegravir and rilpivirine, in the plasma of HIV-positive patients.
    Tempestilli M; Ammassari A; D'Avolio A; Cicalini S; Gallo AL; Fazio S; Antinori A; Pucillo LP
    Biomed Chromatogr; 2018 May; ():e4274. PubMed ID: 29726595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma.
    Simiele M; Ariaudo A; De Nicolò A; Favata F; Ferrante M; Carcieri C; Bonora S; Di Perri G; De Avolio A
    J Pharm Biomed Anal; 2017 May; 138():223-230. PubMed ID: 28219799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an HPLC-UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients.
    Charbe N; Baldelli S; Cozzi V; Castoldi S; Cattaneo D; Clementi E
    J Pharm Anal; 2016 Dec; 6(6):396-403. PubMed ID: 29404009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
    Aouri M; Calmy A; Hirschel B; Telenti A; Buclin T; Cavassini M; Rauch A; Decosterd LA
    J Mass Spectrom; 2013 May; 48(5):616-25. PubMed ID: 23674286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Validation of a Chromatographic Ultraviolet Method for the Simultaneous Quantification of Dolutegravir and Rilpivirine in Human Plasma.
    Cozzi V; Charbe N; Baldelli S; Castoldi S; Atzori C; Cattaneo D; Clementi E
    Ther Drug Monit; 2016 Jun; 38(3):407-13. PubMed ID: 26885814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.
    Bennetto-Hood C; Tabolt G; Savina P; Acosta EP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 945-946():225-32. PubMed ID: 24361860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.
    Prathipati PK; Mandal S; Destache CJ
    J Pharm Biomed Anal; 2016 Sep; 129():473-481. PubMed ID: 27497648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
    Taramasso L; Tatarelli P; Ricci E; Madeddu G; Menzaghi B; Squillace N; De Socio GV; Martinelli C; Gulminetti R; Maggi P; Orofino G; Vichi F; Di Biagio A; Bonfanti P;
    BMC Infect Dis; 2018 Jul; 18(1):357. PubMed ID: 30064371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPLC-MS/MS method for the simultaneous quantification of dolutegravir, elvitegravir, rilpivirine, darunavir, ritonavir, raltegravir and raltegravir-β-d-glucuronide in human plasma.
    Zheng Y; Aboura R; Boujaafar S; Lui G; Hirt D; Bouazza N; Foissac F; Treluyer JM; Benaboud S; Gana I
    J Pharm Biomed Anal; 2020 Apr; 182():113119. PubMed ID: 32004775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of an HPLC method for quantification of dolutegravir in human plasma.
    Li D; Fu Q; Du X; Li T
    Biomed Chromatogr; 2023 Oct; 37(10):e5708. PubMed ID: 37605611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.
    Parsons TL; Marzinke MA
    J Pharm Biomed Anal; 2016 Nov; 131():333-344. PubMed ID: 27632783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.
    D'Avolio A; Siccardi M; Sciandra M; Baietto L; Bonora S; Trentini L; Di Perri G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Nov; 859(2):234-40. PubMed ID: 17964231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Juluca for Human Immunodeficiency Virus Infection Treatment in Virologically Suppressed Adults in Taiwan.
    Anderson SJ; Hsu CY; Ou HT; Ko NY; Yang CT; Lopes S
    Value Health Reg Issues; 2021 May; 24():216-223. PubMed ID: 33857719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.
    D'Avolio A; Baietto L; Siccardi M; Sciandra M; Simiele M; Oddone V; Bonora S; Di Perri G
    Ther Drug Monit; 2008 Dec; 30(6):662-9. PubMed ID: 18824956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development, validation and clinical implementation of a UPLC-MS/MS bioanalytical method for simultaneous quantification of cabotegravir and rilpivirine E-isomer in human plasma.
    Bevers LAH; van Ewijk-Beneken Kolmer EWJ; Te Brake HML; Burger DM
    J Pharm Biomed Anal; 2024 Jan; 238():115832. PubMed ID: 37976991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Validated Method for Quantification of Dolutegravir Using Ultra Performance Liquid Chromatography Coupled With UV Detection.
    Wang X; Penchala SD; Amara A; Else L; McClure M; Boffito M
    Ther Drug Monit; 2016 Jun; 38(3):327-31. PubMed ID: 26859200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database.
    Hsu R; Fusco J; Henegar C; Mounzer K; Wohlfeiler M; Vannappagari V; Aboud M; Curtis L; Fusco G
    Ther Adv Drug Saf; 2018 Dec; 9(12):675-686. PubMed ID: 30546862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.
    Else L; Watson V; Tjia J; Hughes A; Siccardi M; Khoo S; Back D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jun; 878(19):1455-65. PubMed ID: 20427248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples.
    Tsuchiya K; Ohuchi M; Yamane N; Aikawa H; Gatanaga H; Oka S; Hamada A
    Biomed Chromatogr; 2018 Feb; 32(2):. PubMed ID: 28762239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
    Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
    Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.